Current Report Filing (8-k)
January 05 2018 - 4:03PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): January 3, 2018
MONSTER DIGITAL, INC.
(Exact Name of Registrant as Specified
in Charter)
Delaware
|
|
001-37797
|
|
27-3948465
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
2655 First Street, Suite 250
Simi Valley, California 93065
|
|
93065
|
(Address of Principal Executive Office)
|
|
(Zip Code)
|
Registrant’s telephone number,
including area code: (805) 915-4775
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (Section 240.12b-2 of this chapter).
þ
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
o
Item 1.01 Entry into a Material Definitive
Agreement
Extension
of Outside Closing Date for Merger
On January
3, 2018, Monster Digital, Inc., (the “Company” or “Monster Digital”), the Company’s wholly-owned
subsidiary Monster Merger Sub (“Merger Sub”) and Innovate Biopharmaceuticals, Inc. (“Innovate”)
agreed
to extend the outside closing date (the "Closing") of their previously announced reverse merger ("Merger").
The Company and Innovate had originally planned to close the transaction
by January 3, 2018 but the final preparations for the Closing are taking more time than expected.
The
Company, Merger Sub and Innovate have amended the Agreement and Plan of Merger and Reorganization dated July 3, 2017 (the “Merger
Agreement”) to provide that the outside termination date for the Merger will be January 26, 2018.
A
copy of the Amendment to the Merger Agreement is attached hereto as Exhibit 2.1.
Item 7.01 Regulation FD Disclosure
Press Release
On January 4,
2018, the Company issued a press release announcing the extension of the outside closing date for the Merger with Innovate also
announcing significant corporate developments; potential delisting of common stock and settlement with Monster, Inc. A copy of
the press release is attached hereto as Exhibit 99.1.
The information in this Current Report
on Form 8-K furnished pursuant to Items 7.01 and the press release included as Exhibit 99.1 of Item 9.01 shall not be deemed “filed”
for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that
Section. This information shall not be incorporated by reference into any registration statement pursuant to the Securities Act
of 1933, as amended. The furnishing of the information in this Current Report on Form 8-K is not intended to, and does not, constitute
a representation that such furnishing is required by Regulation FD or that the information contained in this Current Report on
Form 8-K constitutes material investor information that is not otherwise publicly available.
Item 8.01 Other Events.
Potential
for common stock to be delisted.
On January 4, 2018, the Company announced that it
has determined that it will be unable to regain compliance for continued listing of its common stock on the NASDAQ Capital Market
by the previously reported January 3, 2018 deadline set by The NASDAQ Stock Market LLC Hearings Panel (the “Panel”).While
the Company has been working diligently with Innovate to complete the Merger, the Company and Innovate, as reported above, have
determined that they will be unable to achieve these objectives prior to the January 3, 2018 deadline.
The Company has
requested that the Panel grant a further extension of the deadline until January 26, 2018. The Company can give no assurance that
the Panel will grant such an extension. If the Panel does not grant the Company’s requested extension, based on the listing
requirements of NASDAQ, the Company’s common stock will be delisted from the Nasdaq Capital Market. The Company's common
stock is currently traded on the NASDAQ Capital Market under the trading symbol “MSDI.” The Company has filed an application
and is taking the steps necessary to have its common stock quoted for trading in the OTCQB US Market (“OTCQB”), operated
by OTC Markets, Inc., under the same trading symbol of “MSDI.”
The Company expects to
hear back from the Panel by the end of this week, but cannot give any assurance that a decision will be reached by then. If the
Panel does not grant an extension and the Company’s common stock is delisted from the NASDAQ Capital Market, trading will
commence on the OTCQB the next trading day.
To the
extent that the Company’s common stock is delisted and following commencement of trading of its common stock on the OTCQB,
the Company’s common stock will continue to be registered under the Exchange Act and the Company will continue to file financial
reports that will be available on the SEC's website,
www.sec.gov
.
Settlement Agreement with Monster,
Inc.
The Company and Monster Inc., (formally known as Monster Cable Products, Inc.) announced on January 4, 2018 that they
have entered into a settlement agreement providing for the early termination of the License Agreement for the “Monster”
names and trademarks. Pursuant to the new understanding, Monster Digital will cease using the Monster names and trademarks on or
before February 1, 2018. Terms of the settlement were not disclosed.
The
information in this item shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934
(the “Exchange Act”), or otherwise subject to the liabilities of Section 18, nor shall it be deemed incorporated by
reference in any of the Company’s filings under the Securities Act of 1933, as amended or the Exchange Act, except to the
extent, if any, expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
See the Exhibit Index set forth below
for a list of exhibits included with this Form 8-K.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
MONSTER DIGITAL, INC.
|
|
|
|
|
|
/s/ David Olert
|
Date: January 5, 2018
|
David Olert
|
|
Chief Financial Officer
|
EXHIBIT INDEX
Innovate Biopharmaceutic... (NASDAQ:INNT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Innovate Biopharmaceutic... (NASDAQ:INNT)
Historical Stock Chart
From Apr 2023 to Apr 2024